<a href="https://laohu8.com/S/FTFI">First Berlin</a> Equity Research Raises <a href="https://laohu8.com/S/INRLF">Valneva SE</a> Price Target to €6.80
First Berlin Equity Research has published an update on Valneva SE, maintaining a "Buy" recommendation and raising the 12-month price target from €6.30 to €6.80. Analyst Simon Scholes cited the advanced clinical development of Valneva's Lyme disease vaccine candidate, VLA15, which is being developed in partnership with Pfizer. All vaccinations in the pivotal phase 3 trial of VLA15 have been completed, with results expected in the first half of next year. Subject to positive outcomes, Pfizer plans to seek regulatory approval in Europe and the U.S. in 2026, with a potential launch in autumn 2027. The new price target reflects increased expectations for VLA15, outweighing recent downward adjustments to forecasts for other Valneva products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24344), on December 08, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。